Completed PHASE2 INTERVENTIONAL 2-arm NCT00299286

Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer (MAPLE)

A Double Blind Short-Term Presurgical Study Assessing the Molecular Antiproliferative Predictors of Lapatinib's Effects in Breast Cancer

Sponsor: GlaxoSmithKline

Conditions Breast Cancer

Interventions Lapatinib Lapatinib-Placebo

Updated 5 times since 2017 Last updated: Aug 3, 2012 Started: Jun 30, 2007 Primary completion: Aug 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and is currently completed. GlaxoSmithKline leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Study Description(click to expand)

Randomised multi centre double blind pre-surgical study in women with a histological diagnosis of breast cancer by core biopsy.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Institute of Cancer Research, United Kingdom

Data source: Institute of Cancer Research, United Kingdom

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom